GlaxoSmithKline's JV ViiV Healthcare says trial of injectable HIV treatment met objectives

Writer,

ViiV Healthcare, a GlaxoSmithKline-Pfizer joint venture, said its injectable HIV treatment had met its primary goal in a clinical trial, reducing the number of treatments needed every year, compared to an oral treatment.

'The study met its primary endpoint, showing that the long-acting regimen of cabotegravir and rilpivirine, injected every two months, was non-inferior to cabotegravir and rilpivirine administered every month at Week 48,' the company said.

'The ATLAS-2M study results mean that people living with HIV could maintain viral suppression with six total treatments per year, instead of a daily oral treatment 365 times per year, it added.

The study was designed to demonstrate the non-inferior antiviral activity and safety of cabotegravir and rilpivirine administered every eight weeks (two months) compared to every four weeks (monthly) over a 48-week treatment period in adults living with HIV-1 infection, whose viral load was suppressed and who were not resistant to cabotegravir or rilpivirine.


Related content

Broker Forecast - Credit Suisse issues a broker note on GlaxoSmithKline PLC

Credit Suisse today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1860p (from 1800p).

Broker Forecasts data provided...

Thu, 16/01/2020 - 09:30


Broker Forecast - Societe Generale issues a broker note on GlaxoSmithKline PLC

Societe Generale today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 2300p (from 2200p).

Broker Forecasts data provided...

Thu, 09/01/2020 - 13:40


Broker Forecast - Morgan Stanley issues a broker note on GlaxoSmithKline PLC

Morgan Stanley today reaffirms its underweight investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1740p (from 1640p).

Broker Forecasts data provided...

Mon, 06/01/2020 - 12:00


Broker Forecast - JP Morgan Cazenove issues a broker note on GlaxoSmithKline PLC

JP Morgan Cazenove today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1900p (from 1700p).

Broker Forecasts data...

Mon, 06/01/2020 - 10:30


GlaxoSmithKline says HIV joint venture treatment rejected by FDA

GlaxoSmithKline confirmed that its ViiV Healthcare joint venture with Pfizer and Shionogi had received a so-called complete response letter from the US Food and Drug...

Mon, 23/12/2019 - 07:22